As of June 30, 2026, AB Science SA carries a market capitalization of 64.83M, placing it among publicly traded companies globally. Its enterprise value stands at 75.38M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 64.83M |
| Enterprise Value | 75.38M |
AB Science SA's next confirmed earnings release is scheduled for April 23, 2027.
| Earnings Date | 4/23/2027 |
As of June 30, 2026, AB Science SA has 73.25M shares outstanding.
| Shares Outstanding | 73.25M |
These figures are as of June 30, 2026.
| PB Ratio | -2.89 |
| P/TBV Ratio | -2.75 |
As of June 30, 2026, AB Science SA maintains a current ratio of 0.85, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.85 |
| Quick Ratio | 0.59 |
| Debt / Equity | -86.99 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 36.00 |
As of the close on November 17, 2026, AB Science SA's stock has declined approximately 49.22% over the past 52 weeks. The 50-day moving average sits at 0.60, while the 200-day moving average is 0.88.
| 52-Week Price Change | -49.22% |
| 50-Day Moving Average | 0.60 |
| 200-Day Moving Average | 0.88 |
As of June 30, 2026, AB Science SA holds 8.98M in cash and equivalents against 19.53M in total debt, resulting in a net debt position of 9.63M. Total book value stands at -22.45M, with working capital of -2.33M providing operational flexibility.
| Cash & Cash Equivalents | 8.98M |
| Total Debt | 19.53M |
| Net Debt | 9.63M |
| Equity (Book Value) | -22.45M |
| Book Value Per Share | -0.31 |
| Working Capital | -2.33M |
Already premium?